SAV1 and non-small cell lung carcinoma: Even though the antiproliferative activity was not as potent as that of GEF alone (1 μM) or SAV alone (2 nM), it was time- and concentration-dependent, and GEF-resistance did not affect the antiproliferative activity of either ARu-B and Ru-B, implying that these compounds may serve as chemotherapeutic agents for treating NSCLC.